JonesTrading analyst Justin Walsh has reiterated their bullish stance on RAPP stock, giving a Buy rating on December 2.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Justin Walsh has given his Buy rating due to a combination of factors including the promising clinical data from Rapport Therapeutics’ RAP-219. The recent update at the 2025 American Epilepsy Society Annual Meeting highlighted significant reductions in long episodes and clinical seizures, with 24% of patients achieving seizure freedom. The treatment’s efficacy was consistent regardless of the baseline severity of the patients’ conditions, and those with moderate or greater impairment reported improved quality of life.
Furthermore, the company’s strategic plans to advance RAP-219 into Phase III trials and the potential for substantial revenue generation in the U.S. and Europe by 2035 underpin the positive outlook. The continued development of RAP technology is expected to be both clinically effective and commercially viable across multiple CNS indications, supporting long-term value for shareholders.
In another report released on December 2, BTIG also initiated coverage with a Buy rating on the stock with a $47.00 price target.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RAPP in relation to earlier this year.